Lupus erythematosus - I-Lupus Erythematosus
☆ AI Dermatology — Free Service
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Ibonakala njenge‑erythema elincane.
I-butterfly rash ivame ukuvela ebusweni.
relevance score : -100.0%
ReferencesUkukhomba nokuhlukanisa i‑cutaneous lupus erythematosus (CLE) kubangela izinselele ekuxilongeni, futhi kuhlukanisa kusuka ku‑systemic lupus erythematosus ngokuzibandakanya kwesikhumba. Ucwaningo lwakamuva lusikhanyisela ezicini zofuzo, ezemvelo, kanye nezamasosha omzimba ezithinta i‑CLE. Ukungeniswa kwezidakamizwa kuvele njengesinye sezimbangela ezibaluleke kakhulu ze‑CLE. Ukwelashwa kuhilela ukwelashwa kwesikhumba kanye nesistimu, okuhlanganisa ama‑biologics athembisayo (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059), asebenza ngempumelelo ezivivinyweni zomtholampilo.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) ihlanganisa izimo ezihlukahlukene zesikhumba, ezithile zazo zingahlangana nezinkinga zempilo ezibanzi. Ihlukaniswa ngezinhlobo ezahlukene, njenge‑acute CLE (ACLE), i‑sub‑acute CLE (SCLE), ne‑chronic CLE (CCLE). I‑CCLE iqukethe i‑discoid lupus erythematosus (DLE), i‑LE profundus (LEP), i‑chilblain cutaneous lupus, ne‑lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus yiqembu lezifo ezizimele ezingathinta izingxenye ezahlukene zomzimba. Ezinye izinhlobo, njenge‑systemic lupus erythematosus (SLE), zithinta izitho eziningi, kanti ezinye, njenge‑cutaneous lupus erythematosus (CLE), zithinta kakhulu isikhumba. Sihlukanisa izinhlobo ezahlukene ze‑CLE ngokusekelwe ekuhlanganiseni kwezimpawu zomtholampilo, ukuhlolwa kwezicubu, nokuhlolwa kwegazi, kodwa kunomehluko omkhulu phakathi kwabantu. Izinkinga zesikhumba zivame ukuvela ngenxa yezinto ezifana nokuchayeka elangeni, ukubhema, noma imithi ethile.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Imbangela ye‑I-Lupus Erythematosus (Lupus erythematosus) ayicacile. Kumawele afanayo, uma elinye lithintekile, kunethuba elingu‑24 % lokuthi elinye libe nalo. Amahomoni ocansi abesifazane, ukuchayeka elangeni, ukubhema, ukushoda kwevithamini D, kanye nezifo ezithile kukholakala ukuthi zandisa ingozi.
Ukwelashwa kungahlanganisa ama-NSAID, i-corticosteroids, ama-immunosuppressants, i-hydroxychloroquine, ne-methotrexate. Noma i-corticosteroids iyasebenza, ukusetshenziswa kwayo isikhathi eside kungaholela emiphumeleni engemihle.